Bruce Cheson, MD
Patients with relapsed/refractory non-Hodgkin lymphoma (NHL) have limited options for treatment, and effective advancedstage therapies must be developed for many subtypes of the disease. In the search for solutions, investigators are turning to combination therapies.
“The study was designed to start with monotherapy treatments and move to combinations in later stages of the trial. The future cohorts will evaluate umbralisib and ublituximab for indolent lymphoma, as well,” said Cheson, who is a professor of medicine, deputy chief of hematology and oncology, and head of hematology and cellular therapy at the Lombardi Comprehensive Cancer Center.
... to read the full story